United States

People: Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

18 Oct 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Southwell, David 

Mr. David. P. Southwell is President, Chief Executive Officer, Director of the Company. From March 2010 to October 2012, Mr. Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences, Inc., or Human Genome Sciences, which is owned by GlaxoSmithKline plc. Prior to his time at Human Genome Sciences, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Sepracor Inc. from July 1994 to July 2008. Mr. Southwell has also served on the Board of Directors of PTC Therapeutics Inc. since December 2005 and THL Credit, Inc. since June 2007. Mr. Southwell received a B.A. from Rice University and an M.B.A. from Dartmouth College.

Basic Compensation

Total Annual Compensation, USD 686,739
Restricted Stock Awards, USD 2,275,000
Long-Term Incentive Plans, USD --
All Other, USD 1,098,740
Fiscal Year Total, USD 4,060,480

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --